Published in Pharmgenomics Pers Med on June 19, 2014
A decision support tool for appropriate glucose-lowering therapy in patients with type 2 diabetes. Diabetes Technol Ther (2014) 0.76
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med (2008) 35.49
Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med (2008) 25.70
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia (2012) 10.74
U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes (1995) 8.95
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes (2009) 8.70
Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract (2009) 7.06
Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care (2003) 6.63
AACE comprehensive diabetes management algorithm 2013. Endocr Pract (2013) 4.88
Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia (2010) 4.33
Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study. Diabetes Care (2011) 4.30
Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2012) 3.74
Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med (2011) 3.54
Management of type 2 diabetes: new and future developments in treatment. Lancet (2011) 2.57
Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism (2011) 1.41
Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. J Clin Endocrinol Metab (2010) 1.34
The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev (2010) 1.28
Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management. Int J Clin Pract (2010) 1.06
To what extent is the new position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) 'personalised'? Diabetologia (2012) 1.05
Design of a decision support system to help clinicians manage glycemia in patients with type 2 diabetes mellitus. J Diabetes Sci Technol (2011) 0.95
The Individualized Target HbA1c: A New Method for Improving Macrovascular Risk and Glycemia Without Hypoglycemia and Weight Gain. Rev Diabet Stud (2009) 0.94
Evaluation of physician preferences for guideline implementation. Am J Med Qual (1999) 0.92
Personalizing treatment in type 2 diabetes: a self-monitoring of blood glucose inclusive innovative approach. Diabetes Technol Ther (2012) 0.89
Glycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances. Diabetes Obes Metab (2010) 0.89
Finnish Current Care Guideline for Diabetes: interactive approach to improve individualised treatment. Diabetologia (2011) 0.82
Which diet for prevention of type 2 diabetes? A meta-analysis of prospective studies. Endocrine (2014) 1.04
Diabetes and sexual dysfunction: current perspectives. Diabetes Metab Syndr Obes (2014) 0.94
Incidence and risk factors for severe and symptomatic hypoglycemia in type 1 diabetes. Results of the HYPOS-1 study. Acta Diabetol (2015) 0.94
Sexual activity in midlife women and beyond. JAMA Intern Med (2014) 0.91
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial. Diabetes Care (2016) 0.86
Interplay among patient empowerment and clinical and person-centered outcomes in type 2 diabetes. The BENCH-D study. Patient Educ Couns (2015) 0.83
Mediterranean diet and type 2 diabetes. Diabetes Metab Res Rev (2014) 0.83
Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit? Endocrine (2016) 0.81
Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects. Pituitary (2016) 0.81
Metabolic syndrome and cancer: holistic or reductionist? Endocrine (2013) 0.81
Lipodystrophy in Insulin-Treated Subjects and Other Injection-Site Skin Reactions: Are We Sure Everything is Clear? Diabetes Ther (2016) 0.80
Correlates of diabetes-related distress in type 2 diabetes: Findings from the benchmarking network for clinical and humanistic outcomes in diabetes (BENCH-D) study. J Psychosom Res (2015) 0.79
Particulate matter pollutants and risk of type 2 diabetes: a time for concern? Endocrine (2015) 0.79
New guidelines for metabolic targets in diabetes: clinician's opinion does matter. Endocrine (2014) 0.77
Glucose, cholesterol, and blood pressure: is lower always better for type 2 diabetes? Endocrine (2016) 0.76
The complex interplay between clinical and person-centered diabetes outcomes in the two genders. Health Qual Life Outcomes (2017) 0.75
Acarbose vs metformin for new-onset type 2 diabetes. Lancet Diabetes Endocrinol (2014) 0.75
Peripheral Arterial Disease and Cardiovascular Risk: The Role of Mediterranean Diet. Angiology (2014) 0.75
Insulin treatment of people with diabetes mellitus and chronic liver disease. Ann Hepatol (2016) 0.75
Lipodistrophy and Associated Risk Factors in Insulin-Treated People With Diabetes. Int J Endocrinol Metab (2016) 0.75
Anti-inflammatory Effect of Mediterranean Diet in Type 2 Diabetes Is Durable: 8-Year Follow-up of a Controlled Trial. Diabetes Care (2016) 0.75